GLP-1 Drugs and Other Emerging Therapies May Help Prevent Alcohol Relapse in Liver Disease Patients
GLP-1 receptor agonists and FGF21 analogs are among emerging peptide-based therapies showing early promise for preventing alcohol relapse in people with liver disease, but existing proven drugs remain dramatically underused.
Quick Facts
What This Study Found
This review examines drugs that can prevent alcohol relapse in patients with alcohol-associated liver disease (ALD). Established medications like naltrexone and acamprosate reduce relapse in general alcohol use disorder but have limited data specifically in liver disease patients. Baclofen is the only drug tested in randomized trials in patients with cirrhosis, showing early benefit but mixed results in later studies.
Notably, emerging peptide-based therapies show early promise: GLP-1 receptor agonists, FGF21 (fibroblast growth factor-21) analogs, and psilocybin are all showing early signals for reducing alcohol use. Despite guideline support, these medications remain dramatically underused due to stigma, lack of provider training, and fragmented care.
Key Numbers
Established drugs: naltrexone, acamprosate, baclofen · Emerging agents: GLP-1 RAs, FGF21 analogs, psilocybin · pharmacotherapy remains underutilized in ALD
How They Did This
This is a narrative review that summarizes the published evidence for pharmacotherapies used to prevent alcohol relapse, with a focus on their application in patients with alcohol-associated liver disease. The authors evaluate both established and emerging drug therapies and discuss barriers to their clinical adoption.
Why This Research Matters
Alcohol-associated liver disease is a leading cause of liver transplantation, and relapse after abstinence is the primary driver of disease progression and post-transplant failure. The emergence of GLP-1 receptor agonists and FGF21 analogs as potential anti-relapse therapies is particularly significant because these peptide drugs could simultaneously treat metabolic liver disease and reduce alcohol cravings — addressing two problems with one medication class.
The Bigger Picture
The discovery that GLP-1 receptor agonists may reduce alcohol use has been one of the most unexpected and exciting developments in addiction medicine. Originally developed for diabetes and obesity, these peptide drugs appear to dampen reward-seeking behavior more broadly. Combined with FGF21 analogs — another peptide-based therapy with liver-protective and appetite-modulating properties — the field may be approaching a paradigm shift where metabolic peptide drugs become dual-purpose treatments for both liver disease and the addiction driving it.
What This Study Doesn't Tell Us
As a narrative review, this paper does not present new data or conduct systematic analysis. Most drug evidence comes from general alcohol use disorder populations rather than liver disease patients specifically. The emerging therapies (GLP-1 RAs, FGF21 analogs) are described as having 'early signals' only, meaning robust clinical trial data is still needed.
Questions This Raises
- ?Will GLP-1 receptor agonists prove effective for alcohol relapse prevention in dedicated randomized controlled trials in liver disease patients?
- ?Could FGF21 analogs simultaneously treat liver fibrosis and reduce alcohol cravings, making them ideal dual-action drugs for ALD?
- ?What combination of pharmacotherapy and behavioral intervention will prove most effective for preventing relapse in the transplant setting?
Trust & Context
- Key Stat:
- Pharmacotherapy widely underutilized Despite guideline support, anti-relapse drugs are rarely prescribed for alcohol-associated liver disease patients due to stigma, provider inexperience, and fragmented care
- Evidence Grade:
- This is a narrative review published in a gastroenterology journal. It summarizes existing evidence rather than generating new data. The established drugs have moderate evidence from general AUD populations, while the emerging peptide therapies (GLP-1 RAs, FGF21 analogs) have only early-stage evidence, warranting a low overall evidence rating.
- Study Age:
- Published in 2025, this is a very current review that captures the latest thinking on pharmacotherapy for alcohol relapse in liver disease, including the emerging interest in GLP-1 drugs for addiction.
- Original Title:
- Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.
- Published In:
- Current gastroenterology reports, 27(1), 74 (2025)
- Authors:
- Zhang, Wei(11), Hwang, Soo Young(2), Luther, Jay(2)
- Database ID:
- RPEP-14535
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can GLP-1 drugs like semaglutide help people stop drinking?
Early evidence suggests GLP-1 receptor agonists may reduce alcohol use by dampening reward-seeking behavior in the brain. Several observational studies and early trials have shown promising signals, but dedicated randomized controlled trials are still needed to confirm this effect. The potential is exciting because these drugs could treat both metabolic disease and addiction simultaneously.
Why aren't doctors prescribing anti-relapse drugs for liver disease patients?
Despite guideline recommendations, several barriers prevent widespread use: stigma around addiction, lack of training among hepatologists in addiction medicine, concerns about drug safety in patients with liver damage, and fragmented care systems where liver specialists and addiction specialists rarely coordinate. Integrated care programs are beginning to address these gaps.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14535APA
Zhang, Wei; Hwang, Soo Young; Luther, Jay. (2025). Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.. Current gastroenterology reports, 27(1), 74. https://doi.org/10.1007/s11894-025-01026-x
MLA
Zhang, Wei, et al. "Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.." Current gastroenterology reports, 2025. https://doi.org/10.1007/s11894-025-01026-x
RethinkPeptides
RethinkPeptides Research Database. "Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associ..." RPEP-14535. Retrieved from https://rethinkpeptides.com/research/zhang-2025-pharmacotherapy-to-prevent-alcohol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.